{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-008313","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.617416+00:00","generated_at":"2026-06-17T11:39:46.560351+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioCardia reports FY2022 net loss $11.9M, cash runway into Q3 2023; clinical milestones ahead","bullets":["Net loss $11.9M in 2022 vs $12.6M in 2021; revenue $1.4M up from $1.0M.","Cash $7.4M at year-end provides runway into Q3 2023.","CardiAMP Phase III heart failure trial enrolled 119 patients; DSMB cleared, adaptive SAP submitted.","NK1R+ MSC allogeneic trial for HFrEF (BCDA-03) IND approved; first patient expected Q2 2023.","Japan submission for CardiAMP approval planned for Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-008313","json":"https://secwatch.observer/filing/0001437749-23-008313.json","markdown":"https://secwatch.observer/filing/0001437749-23-008313.md","text":"https://secwatch.observer/filing/0001437749-23-008313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774923008313/0001437749-23-008313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774923008313/bcda20230328_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T11:39:46.560351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b4cb1acb93dcf63fd22567e040abd0e0c73a1372","claim":"BioCardia, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774923008313/0001437749-23-008313-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}